Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation



Status:Completed
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:6 - 11
Updated:4/21/2016
Start Date:July 2013
End Date:October 2015

Use our guide to learn which trials are right for you!

A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

This is a Phase 3, 2 part (Part A and Part B), open label, multicenter study to evaluate the
pharmacokinetics, safety and tolerability of lumacaftor in combination with ivacaftor in
subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene.


Inclusion Criteria:

- Confirmed diagnosis of CF defined as:

- with 2 CF-causing mutations

- chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities

- Subjects who weigh > 15 kg without shoes at Screening Visit

- Subjects who are homozygous for the F508del-CFTR mutation

- Subjects with percent predicted Forced Expiratory Volume in 1 second (FEV1) of 70% to
105% (inclusive) (Part A) or ≥40% (Part B) at the screening visit where the predicted
values are adjusted for age, sex, and height using the Wang equation

- Subjects with stable CF disease and who are willing to remain on stable CF medication
regimen

- Able to swallow tablets

Exclusion Criteria:

- History of any illness or condition that might confound the results of the study or
pose an additional risk in administering study drug to the subject

- Acute respiratory infection, pulmonary exacerbation, or changes in therapy for
pulmonary disease within 28 days before Day 1 of the study

- Abnormal liver function as defined in the protocol at Screening

- Abnormal renal function as defined in the protocol at Screening

- History of solid organ or hematological transplantation

- Ongoing participation in another therapeutic clinical study or prior participation in
an investigational drug study within 30 days prior to Screening

- Evidence of lens opacity or cataract at the Screening

- Colonization with organisms associated with a more rapid decline in pulmonary status
at Screening (Part A only)

- A standard 12-lead ECG demonstrating QtcF >450 msec at Screening
We found this trial at
7
sites
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials